Intratumoral Therapy Increases Response to Checkpoint Inhibitor in Triple Negative Breast Cancer, Study Finds

Intratumoral Therapy Increases Response to Checkpoint Inhibitor in Triple Negative Breast Cancer, Study Finds
Combining OncoSec Medical‘s intratumoral therapy, ImmunoPulse IL-12, with an immune checkpoint inhibitor is a promising approach for triple-negative breast cancer patients, a Phase 1 clinical trial  suggests. The approach induced robust objective responses in two patients with metastatic triple-negative breast cancer who had already had received multiple lines of therapy. Such patients typically do not respond

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *